Protein formulations containing amino acids
Provided are stable protein formulations that contain at least one amino acid. In certain embodiments, amino acid combinations either at least two, or three, or four, or more amino acids are included. By virtue of inclusion of the amino acids, the formulation has low viscosity and a protein in the formulations is physically, chemically, and biological stable even at high concentrations. In further embodiments, by virtue of inclusion of the amino acids, a protein in the formulations is physically, chemically, and biological stable even at high concentrations.
1. A stable liquid pharmaceutical formulation comprising:
an antibody, the antibody being adalimumab, alemtuzumab, alirocumab, basiliximab, bevacizumab, daratumumab, infliximab, panitumumab, ranibizumab, rituximab or trastuzumab;
one or more amino acids to stabilize the antibody in the formulation, the one or more amino acids to stabilize the antibody including serine, threonine, alanine, glycine and valine and one or more further amino acids selected from the group consisting of isoleucine, asparagine, glutamine and aspartic acid; and
one or more amino acids to reduce the viscosity of the formulation, the one or more amino acids to reduce viscosity of the formulation including proline,
wherein the viscosity of the formulation is less than 100 cP.
2. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine and isoleucine.
3. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine and asparagine.
4. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine and glutamine.
5. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine and aspartic acid.
6. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine, glutamine and asparagine.
7. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine, glutamine and isoleucine.
8. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine, glutamine and aspartic acid.
9. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine, asparagine and isoleucine.
10. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine, asparagine and aspartic acid.
11. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody are serine, threonine, alanine, glycine, valine, isoleucine and aspartic acid.
12. The formulation of claim 1 , wherein the one or more amino acids to stabilize the antibody and the one or more amino acids to reduce viscosity of the formulation are each present at a concentration of at least 0.1 mg/mL.
13. The formulation of claim 1 , wherein the concentration of proline is from about 1 mg/mL to about 20 mg/mL and, when present in the formulation, the concentration of each of serine, threonine, glycine, alanine, valine, isoleucine and/or asparagine is from about 1 mg/mL to about 20 mg/mL.
14. The formulation of claim 1 , wherein when present in the formulation, the concentration of each of glutamine and/or aspartic acid is from about 1.5 mg/mL to about 10 mg/mL.
15. The formulation of claim 14 , wherein the concentration of each of serine and/or glycine is at least about 20 mg/mL.
16. The formulation of claim 13 , wherein the concentration of each of serine, threonine, glycine, alanine, valine, and/or proline is at least 10 mg/mL.
17. The formulation of claim 13 , wherein the concentration of isoleucine is at least 7 mg/mL.
18. The formulation of claim 13 , wherein the concentration of asparagine is from about 3 mg/mL to about 8 mg/mL.
19. The formulation of claim 14 , wherein the concentration of glutamine is from about 3 mg/mL to about 8 mg/mL.
20. The formulation of claim 15 , wherein the concentration of each of serine and/or glycine is at least 25 mg/mL.
21. The formulation of claim 20 , wherein the concentration of each of serine and/or glycine is at least 30 mg/mL.
22. The formulation of claim 21 , wherein the concentration of serine is at least 35 mg/mL.